Scatterplot of observed barrier scores against knowledge scores (top) and confidence scores (bottom) with linear line of best fit. by Lisa Thiele (6468056)

Subjects:

The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... by Chanel Avenant (409756)

“…The substantial and differential decrease in testosterone and SHBG levels does not explain our previous finding of no detected decrease in risky sexual behavior or sexual function for DMPA-IM or NET-EN users from D0 to 25W. …”

Mean KAP scores and standard deviation at different assessment times. by Chikondi Maluwa (20660522)

Subjects:

No significant diurnal rhythmicity of short chain fatty acids in the blood was observed. by Weiran Shan (16969688)

Mann-Kendall test for the mean temperature index. by Chengyuan Hao (21615653)

“…Secondly, the daily minimum and maximum temperatures increased significantly, which were 0.395°C/10a and 0.200°C/10a respectively<b>—</b>less than the national mean. …”

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

RcbA and RcbB co-operatively decrease motility independent of CaCl₂ concentration. by Shobnom Mustaree (21728815)

Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. by Daisuke Sugahara (2047696)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects: